Chdi Foundation, Inc.

Hoffmann-la Roche Inc.

Michael Edward Prime

Celia Dominguez

Peter David Johnson

Christopher John Brown

John Wityak

Jonathan Bard

Leticia M Toledo-Sherman

William Mitchell

Daniel Clark-Frew

Samuel Coe

Sarah Hayes

Stephen Martin Courtney

Naomi Went

Alex Kiselyov

Richard Waldron Marston

Paula C De Aguiar Pena

Thomas Martin Krülle

Matthew Robert Mills

Sébastien René Gabriel Galan

Paul Richard Giles

Longbin Liu

Matthew Randolf Lee

Thomas Martin Krulle

Duane Higgins

Samantha Brown

Frederick Arthur Brookfield

Douglas Macdonald

Elise Luciennen Paulette Gadouleau

Wolfgang Von Der Saal

Ulrike Reiff

Lothar Kling

Christopher John Yarnold

Thomas Von Hirschheydt

Ignacio Muñoz-Sanjuán

Jonathan Gridley

Daryl Simon Walter

Ignacio Muñoz-Sanjuan

Inaki Morao

Elise Lucienne Paulette Gadouleau

Adrian Kotey

Derek Alexander Weddell

Ian James Wigginton

Malcolm George Taylor

Sebastien Rene Gabriel Galan

William Leonard Mitchell

Ignacio Munoz

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Probes for imaging huntingtin protein

The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

Compounds for targeting mutant huntingtin protein and uses thereof

Provided herein are certain compounds and imaging agents useful for detecting a condition or disorder associated with protein aggregation, compositions thereof, and methods of their use.

Compounds and probes for imaging huntingtin protein

Probes for imaging Huntingtin protein

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. 

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use. 

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use 

Growing community of inventors

Abingdon, United Kingdom

Michael Edward Prime